During this webinar, Dr.
|
As the choices available for anti-obesity pharmacotherapy increase, clinicians are faced with options for addressing key clinical scenarios.
|
This presentation discusses the particular administrative needs and challenges related to treating obesity.
|
Selecting the correct on label or off label medication to treat obesity can be confusing. The acronym RXAOM provides a framework for individualizing the selection process.
|
In June of 2023 the AASLD updated the nomenclature for NAFLD to Metabolic dysfunction-Associated Steatotic Liver Disease(MASLD).
|
Printed Syllabus including lecture slides and case work
|
Printed Syllabus including lecture slides and case work
|
Obesity is a chronic, serious life threatening disease, but treatments exist. Obesity is associated with an increased risk of CVD and CV-associated mortality.
|
Obesity is one of the leading causes of preventable death. Obesity-related increases metabolic and cardiovascular risk occur at a lower body mass index in Asian adults.
|
This session utilizes a direct instructional format to expand on the recent American Academy of Pediatrics Clinical Practice Guidelines for the Evaluation and Treatment of Children and Adolescents
|